anti-HER2/TRAIL-R2 CAR T-cell therapy (Baylor College of Medicine)

N/A

Report date: 2025/06/11 10:49:05

Base Information

Drug Nameanti-HER2/TRAIL-R2 CAR T-cell therapy (Baylor College of Medicine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunostimulantsReceptor protein-tyrosine kinase erbB-2 modulatorsTumor necrosis factor receptor superfamily member 10B modulators +[4]

TargetsTumor necrosis factor receptor superfamily member 10BReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsMetastatic breast cancer

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBaylor College Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine

Inactive CompaniesN/A

Active IndicationsMetastatic breast cancer

Inactive IndicationsN/A

Other Information

ATC CodeN/A